Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
We review tolerance, side effects, weight trend, and body composition
We label the strength of evidence and flag estimates as estimates never as clinical fact
We identified a convenience sample of health plan members with commercial, managed Medicaid, and Medicare Advantage insurance who filled at least one prescription for a GLP-1 agonist indicated for the treatment of diabetes anytime between January 2018 and December 2023
In 2025, Novo Nordisk submitted Orforglipron for regulatory review by the FDA, but it is not yet approved
US$ 26.36
US$ 21.62
US$ 24.54
